8SV1.F - WPD Pharmaceuticals Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.3665 |
| Open | 0.3700 |
| Bid | 0.3730 x N/A |
| Ask | 0.3855 x N/A |
| Day's Range | 0.3530 - 0.3860 |
| 52 Week Range | 0.0030 - 1.7380 |
| Volume | 44,000 |
| Avg. Volume | 86,056 |
| Market Cap | 12.237M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- GlobeNewswire
WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to announce that on May 21, 2020 Wake Forest University received a patent from the United States Patent and Trademark Office (“USPTO”) for a patent titled “EphA3 and Multi-Valent Targeting of Tumors” (under application number 15/958,608). The patent is exclusively licensed to WPD, and the patent relates to the WPD101 drug candidate, used in the therapy of glioblastoma multiform (“GBM”).
- MarketWatch
UPDATE: Moleculin Biotech, CNS Pharma shares remain halted on Nasdaq
Moleculin Biotech Inc. and CNS Pharmaceuticals Inc. said Monday their shares remain halted on Nasdaq with the exchange seeking additional information from each company. Shares werehalted temporarily on May 1 by the Securities and Exchange Commission in a halt that was meant to expire at 11.59 p.m. on May 15. The halt came because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19, the SEC said. Moleculin's stock was halted along with CNS and WPD Pharmaceuticals Inc. , because of questions relating to a drug candidate called WP1122. CNS was working with WPD to develop the drug; WPD had previously licensed rights to a portfolio of drug candidates including WP1122 from Moleculin Biotech for certain regions.
- GlobeNewswire
WPD Pharmaceuticals To Resume Trading
VANCOUVER, British Columbia, May 15, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces that.
- GlobeNewswire
WPD Pharmaceuticals Comments on SEC Order
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, clarifies the temporary suspension on its trading ordered by the United States Securities and Exchange Commission (“SEC”). After trading hours on May 1, 2020 the SEC issued an Order (the “Order”) in the public interest and protection of investors requiring a suspension in the trading of securities of WPD Pharmaceuticals Inc. pursuant to Section 12(k) of the Securities Exchange Act of 1934.
- MarketWatch
SEC takes action against three more companies over COVID-19 claims
The Securities and Exchange Commission temporarily halted trading in three more stocks on Monday because of questions regarding the accuracy of information in the marketplace about a drug candidate for the coronavirus illness COVID-19.
- GlobeNewswire
WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
The US Phase 2 trial Sponsor will be CNS and the Polish Phase 2 trial Sponsor will be WPD, a Polish corporation founded by Professor Waldemar Priebe, founder of both WPD and CNS. The Company expects to initiate both its Phase 2 US and Polish trial of Berubicin in adults with GBM during the second half of 2020.
- PR Newswire
CNS Pharmaceuticals and WPD Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system in collaboration with WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) ("WPD") a clinical stage pharmaceutical company, today announced it has identified several leading medical institutions in Poland to conduct its Berubicin Phase 2 clinical trial in adults with glioblastoma multiforme ("GBM"), an aggressive and incurable form of brain cancer.
- GlobeNewswire
WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial
VANCOUVER, British Columbia, April 29, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.
- GlobeNewswire
WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin
VANCOUVER, British Columbia, April 24, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to.
- GlobeNewswire
WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity
WPD Pharmaceuticals Inc. (CSE:WBIO) (8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company is pleased to provide an update on its Annamycin drug candidate. The phase 1 trial met its objective of demonstrating the safety of Annamycin.
- GlobeNewswire
WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
VANCOUVER, British Columbia, April 21, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company along with its.
- GlobeNewswire
WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company announces that its license partner, Moleculin Biotech, Inc. (“Moleculin”) will be hosting a web-based investor conference call, today, April 16th at 4:30pm ET to explain the significance of the recent discovery that the active compound in WP1122 drug candidate has been shown to reduce replication of SARS-CoV-2 by 100%. WPD has licensed rights to a portfolio of drug candidates, including WP1122 through Moleculin.
- PR Newswire
CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that independent research by the University of Frankfurt found 2-deoxy-D-glucose ("2-DG") to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing.
- GlobeNewswire
WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company reports that the Company anticipates to resume trading at market open on Monday, April 13, 2020. WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules.
- GlobeNewswire
WPD Pharmaceuticals Clarifies News on Licensed Drug Candidate
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, at the request of IIROC, clarifies its press release released yesterday regarding the independent research on its WP1122 drug compound. In the prior press release, WPD disclosed that independent research found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(MBRX) for use in 31 countries.
- GlobeNewswire
WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD in collaboration with its development partner CNS Pharmaceuticals, Inc. (“CNS”)(CNSP) intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.
- GlobeNewswire
WPD Pharmaceuticals Provides Corporate Update
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide a corporate update on its business and the continued development of its portfolio of drug candidates. “We have made great strides advancing our comprehensive drug portfolio with our license partners, Moleculin Biotech and CNS Pharmaceuticals and we are looking forward to executing on our growth strategy.”
- GlobeNewswire
WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is excited to announce that Dr. Waldemar Debinski, inventor of WPD101, WPD102 and WPD103 drug candidates has joined its Scientific Advisory Board. The Company’s name comes from the names of inventors Dr. Waldemar Priebe and Dr. Waldemar Debinski, which creates the “WPD” in WPD Pharmaceuticals.
- GlobeNewswire
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces it has entered into a development agreement (the “Agreement”) with CNS Pharmaceuticals, Inc. (“CNS”)(CNSP) for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2. WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(MBRX).
- PR Newswire
CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company primarily specializing in the development of novel treatments for cancers of the brain and central nervous system, announces it has entered into an agreement with WPD Pharmaceuticals Inc. (CSE: WBIO) for the development of several preclinical drug candidates including WP1122, which is being tested on a range of viruses including the coronavirus SARS-CoV-2. WPD Pharmaceuticals previously licensed rights to a portfolio of drug candidates, including WP1122, from Moleculin Biotech, Inc. for certain territories. WPD Pharmaceuticals was founded by Dr. Waldemar Priebe, the founder of the Company.
- GlobeNewswire
WPD PHARMACEUTICALS’ WP1122 DRUG TO BE TESTED ON A RANGE OF VIRUSES INCLUDING CORONAVIRUS
VANCOUVER, British Columbia, March 19, 2020 -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces, that.
- GlobeNewswire
WPD PHARMACEUTICALS ANNOUNCES BRAIN CANCER PATIENT FROM BERUBICIN PHASE 1 TRIAL REMAINS CANCER FREE
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that a patient from the Phase 1 clinical trial of its Berubicin drug for the treatment of glioblastoma multiforme ("GBM"), remains cancer free. The clinical trial was conducted by $4Bn pharmaceutical company, Reata Pharmaceuticals, Inc. GBM is an aggressive type of brain cancer and currently, there are no effective therapies approved to treat this disease.
- GlobeNewswire
WPD PHARMACEUTICALS RECEIVED $800,000 REIMBURSEMENT FROM $7.4 MILLION GOVERNMENT GRANT FOR DEVELOPMENT OF GLIOBLASTOMA DRUG
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”) a clinical stage pharmaceutical company, is pleased to announce that it has received from the Polish National Center for Research and Development (“NCRD”) approximately C$800,000 in reimbursement of costs for the development of WPD101. WPD101 is exclusively licensed from Wake Forest University. To date, WPD has received almost C$20 million in government grants for the development of its drug portfolio.
- GlobeNewswire
WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company, is pleased to provide an update that through its license partner, CNS Pharmaceuticals, Inc. (“CNS”)(CNSP), it received positive feedback from the U.S. Food and Drug Administration (“FDA”) for its Pre-IND (Investigational New Drug) meeting proposal to use a lyophilized drug product, Berubicin, in Phase II clinical trials.
- GlobeNewswire
WPD Pharmaceuticals’ Annamycin Received Positive Interim Results From Phase 1/2 Clinical Studies in Acute Myeloid Leukemia
WPD Pharmaceuticals Inc. (CSE:WBIO)(8SV1.F) (the “Company” or “WPD”), a clinical stage pharmaceutical company is pleased to provide an update on the clinical drug studies of Annamycin in Acute Myeloid Leukemia (“AML”). WPD’s license partner Moleculin Biotech, Inc, (“Moleculin”) (MBRX) disclosed additional positive interim safety and efficacy data from one of the two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory AML.
